# A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

> **NCT05590403** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1544 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSVPreF3 OA investigational vaccine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05590403
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-28
- **Primary completion:** 2023-03-13
- **Final completion:** 2024-02-12
- **Target enrollment:** 1544 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05590403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05590403, "A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05590403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*